Hydralazine-induced pulmonary-renal syndrome:  a case report.
Drug-induced lupus erythematosus differs in its manifestation from drug-induced vasculitis. The former is associated with characteristic symptoms that improve following discontinuation, whereas the latter is predominantly an antineutrophil cytoplasmic antibody (ANCA) positive small vessel vasculitis involving the kidneys, skin, and lungs. We present a case of advanced disease in an elderly Caucasian woman requiring corticosteroids, and immunosuppressive therapy, who was on hydralazine for >2 years.
Kalra
Ankur
A
Department of Medicine, Cooper University Hospital, Camden, NJ 08103, USA. ceo@kalrahospital.com
Yokogawa
Naoto
N
Raja
Haroon
H
Palaniswamy
Chandrasekar
C
Desai
Priyank
P
Zanotti-Cavazzoni
Sergio L
SL
Rajaram
Sri-Sujanthy
SS
D000368:Aged; D005260:Female; D005921:Glomerulonephritis / Q000139:chemically induced* / Q000503:physiopathology; D005938:Glucocorticoids / Q000627:therapeutic use; D006470:Hemorrhage / Q000139:chemically induced* / Q000503:physiopathology; D006801:Humans; D006830:Hydralazine / Q000009:adverse effects* / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008171:Lung Diseases / Q000139:chemically induced* / Q000503:physiopathology; D014665:Vasodilator Agents / Q000009:adverse effects* / Q000627:therapeutic use
D005938:Glucocorticoids; D007166:Immunosuppressive Agents; D014665:Vasodilator Agents; D006830:Hydralazine